Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$89.45

-0.6 (-0.67%)

, INCY

Incyte

$70.10

-0.3 (-0.43%)

18:33
07/19/18
07/19
18:33
07/19/18
18:33

Lancet study shows benefit of Baricitinib 4 mg for treatment of SLE

Eli Lilly (LLY) and Incyte (INCY) announced that results of a global systemic lupus erythematosus, or SLE, Phase 2 study for baricitinib were published by The Lancet. The study, the first completed Phase 2 study of a JAK inhibitor in SLE, showed that a statistically significant proportion of patients treated with 4 mg of baricitinib achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, the primary endpoint for the trial. Lilly plans to initiate Phase 3 trials to evaluate the safety and efficacy of baricitinib for the treatment of SLE in the second half of 2018. In the study, 314 patients were randomized 1:1:1 to receive placebo, baricitinib 2 mg or baricitinib 4 mg. Patients treated with 4 mg of baricitinib experienced improvements compared to placebo on several pre-specified secondary endpoints. Compared to placebo, a statistically significant greater proportion of patients treated with 4 mg of baricitinib experienced lower overall disease activity at week 24 as measured by the SLE Responder Index 4. A statistically significant greater proportion of patients treated with 4 mg of baricitinib achieved a state of low disease activity, as measured by the Lupus Low Disease Activity State, and experienced improvements in pain from baseline, two exploratory endpoints of the study. The percentage of patients stopping therapy through the 24-week treatment period was 21% in the placebo group, 18% in the 2-mg dosing group and 17% in the 4-mg dosing group. The most common treatment emergent adverse events in the baricitinib groups were upper respiratory tract infections, including viral upper respiratory infections, and urinary tract infections. The frequency of serious adverse events was 5% for placebo, 10.5% in the 2-mg dosing group and 9.6% in the 4-mg dosing group; the most common SAEs were serious infections. One case of deep vein thrombosis was reported in the 4-mg dosing group. There were no deaths, malignancies, major adverse cardiovascular events, tuberculosis, or serious herpes zoster infections.

LLY

Eli Lilly

$89.45

-0.6 (-0.67%)

INCY

Incyte

$70.10

-0.3 (-0.43%)

  • 24

    Jul

  • 31

    Jul

  • 10

    Sep

LLY Eli Lilly
$89.45

-0.6 (-0.67%)

07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/19/18
BMOC
07/19/18
NO CHANGE
Target $80
BMOC
Market Perform
Eli Lilly to have a 'good Q2' on beats from launch franchises, says BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $80 from $78 ahead of its Q2 earnings, saying the company will have a "good" quarter on "beats from its launch franchises Trulicity, Jardiance, and Basaglar". The analyst also keeps his Market Perform rating, adding that while the the pipeline potential of its Galcanezumab and Tanezumab drugs is promising, he believes investors are underappreciating the headwinds around its diabetes program. He see higher risks of an increased biosimilar erosion for Humalog from Sanofi's (SNY) Admelog, and Trulicity competitive pressure from Novo's (NVO) Ozempic in 2019.
INCY Incyte
$70.10

-0.3 (-0.43%)

07/13/18
MSCO
07/13/18
DOWNGRADE
Target $76
MSCO
Equal Weight
Incyte downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison downgraded Incyte to Equal Weight from Overweight as he believes key catalysts are unlikely until 2019 and he expects the stock to trade with the market in the meantime. However, Harrison said he is positive on the depth and diversity of the company's pipeline following the analyst day deep-dive and he thinks 2019 could be a pivotal year. He maintains a $76 price target on Incyte shares.
07/13/18
MSCO
07/13/18
DOWNGRADE
MSCO
Equal Weight
Incyte downgraded to Equal Weight from Overweight at Morgan Stanley
07/13/18
07/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AT&T (T) downgraded to Market Perform from Outperform at Raymond James with analyst Frank Louthan saying he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. 2. Incyte (INCY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Matthew Harrison saying he believes key catalysts are unlikely until 2019 and he expects the stock to trade with the market in the meantime. 3. WisdomTree (WETF) was downgraded to Market Perform from Outperform at Keefe Bruyette and to Neutral from Buy at Citi. 4. Cedar Fair (FUN) downgraded to Neutral from Outperform at Macquarie. 5. Ingredion (INGR) downgraded to Sell from Neutral at Citi with analyst David Driscoll saying he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/18
OPCO
07/18/18
NO CHANGE
Target $70
OPCO
Perform
Incyte price target raised to $70 from $65 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Incyte to $70 from $65 as several options in MPNs with combinations on top of Jakafi could solidify the franchise against potential competition, and early data will be available for several combinations in 2H18 and 2019. The analyst reiterates a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

VLKAY

Volkswagen

$0.00

(0.00%)

, WMT

Walmart

$97.89

-0.74 (-0.75%)

19:37
08/19/18
08/19
19:37
08/19/18
19:37
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

VLKAY

Volkswagen

$0.00

(0.00%)

WMT

Walmart

$97.89

-0.74 (-0.75%)

MSFT

Microsoft

$107.58

-0.07 (-0.07%)

TCEHY

Tencent

$0.00

(0.00%)

STT

State Street

$84.95

0.73 (0.87%)

TWX

Acquired by T

$0.00

(0.00%)

KSS

Kohl's

$76.43

1.68 (2.25%)

BV

BrightView

$17.49

-0.06 (-0.34%)

VZ

Verizon

$54.79

0.51 (0.94%)

ABBV

AbbVie

$98.79

0.6 (0.61%)

LYB

LyondellBasell

$113.07

1.155 (1.03%)

AVGO

Broadcom

$209.27

0.6 (0.29%)

RF

Regions Financial

$19.48

0.09 (0.46%)

SBUX

Starbucks

$53.58

0.53 (1.00%)

CF

CF Industries

$47.52

0.25 (0.53%)

MOS

Mosaic

$29.64

(0.00%)

NTR

Nutrien

$55.95

0.94 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

  • 06

    Nov

VJET

voxeljet

$3.34

-0.17 (-4.84%)

19:14
08/19/18
08/19
19:14
08/19/18
19:14
Recommendations
voxeljet analyst commentary at Piper Jaffray »

voxeljet Q2 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEG

Key Energy

$12.97

-0.03 (-0.23%)

18:30
08/19/18
08/19
18:30
08/19/18
18:30
Hot Stocks
Key Energy appoints Rob Saltiel as new President, CEO »

Key Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 02

    Oct

  • 03

    Oct

TWX

Acquired by T

$0.00

(0.00%)

, CMCSA

Comcast

$35.61

-0.05 (-0.14%)

16:52
08/19/18
08/19
16:52
08/19/18
16:52
Hot Stocks
Box Office Battle: 'Crazy Rich Asians' wins weekend with $25.2M debut »

Warner Bros. (TWX)…

TWX

Acquired by T

$0.00

(0.00%)

CMCSA

Comcast

$35.61

-0.05 (-0.14%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$54.88

1.055 (1.96%)

FOX

21st Century Fox

$44.83

-0.28 (-0.62%)

FOXA

21st Century Fox

$45.37

-0.34 (-0.74%)

LGF.A

Lionsgate

$22.95

-0.11 (-0.48%)

DIS

Disney

$112.44

-0.05 (-0.04%)

VIAB

Viacom

$30.72

0.62 (2.06%)

VIA

Viacom

$35.60

0.1 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

SHLD

Sears

$1.32

-0.135 (-9.28%)

12:28
08/19/18
08/19
12:28
08/19/18
12:28
Periodicals
Sears CEO wants board to sell him Kenmore, pay off debt, WSJ reports »

Sears CEO Edward Lampert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

13:37
08/18/18
08/18
13:37
08/18/18
13:37
Periodicals
Walmart asks beauty suppliers to consider sourcing outside of China, Reuters say »

Walmart has asked some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

13:26
08/18/18
08/18
13:26
08/18/18
13:26
Periodicals
Tencent-backed Qutoutiao files for U.S. IPO, Reuters reports »

Chinese content…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.78

-0.98 (-0.56%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

13:10
08/18/18
08/18
13:10
08/18/18
13:10
Periodicals
Selloff in Chinese internet stocks may shake faith in FANG, Reuters says »

A steep downturn in…

FB

Facebook

$173.78

-0.98 (-0.56%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

NFLX

Netflix

$316.78

-5.51 (-1.71%)

GOOG

Alphabet

$1,199.79

-6.21 (-0.51%)

GOOGL

Alphabet Class A

$1,215.50

-8.05 (-0.66%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

VLKAY

Volkswagen

$0.00

(0.00%)

13:05
08/18/18
08/18
13:05
08/18/18
13:05
Periodicals
Volkswagen CEO was told about emissions software months before, Reuters reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

, TCEHY

Tencent

$0.00

(0.00%)

13:01
08/18/18
08/18
13:01
08/18/18
13:01
Hot Stocks
Walmart, Flipkart announce completion of investment »

Walmart (WMT) and…

WMT

Walmart

$97.89

-0.74 (-0.75%)

TCEHY

Tencent

$0.00

(0.00%)

MSFT

Microsoft

$107.58

-0.07 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

BBOX

Black Box

$1.64

0.09 (5.81%)

12:57
08/18/18
08/18
12:57
08/18/18
12:57
Hot Stocks
Black Box announces sale agreement of Federal Government IT Services Business »

Black Box announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$76.43

1.68 (2.25%)

12:52
08/18/18
08/18
12:52
08/18/18
12:52
Periodicals
Kohl's looking to break cycle, Barron's says »

Kohl's is set to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

STT

State Street

$84.95

0.73 (0.87%)

12:47
08/18/18
08/18
12:47
08/18/18
12:47
Periodicals
State Street selloff looks overdone, Barron's says »

At the moment, State…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

12:42
08/18/18
08/18
12:42
08/18/18
12:42
Periodicals
May be time to sell Walmart, Barron's says »

In a follow-up story,…

WMT

Walmart

$97.89

-0.74 (-0.75%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

VZ

Verizon

$54.79

0.51 (0.94%)

12:39
08/18/18
08/18
12:39
08/18/18
12:39
Periodicals
Verizon remains 'reasonably' priced, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CF

CF Industries

$47.52

0.25 (0.53%)

, MOS

Mosaic

$29.64

(0.00%)

12:36
08/18/18
08/18
12:36
08/18/18
12:36
Periodicals
CF, Mosaic gains have just begun, Barron's says »

CF Industries (CF),…

CF

CF Industries

$47.52

0.25 (0.53%)

MOS

Mosaic

$29.64

(0.00%)

NTR

Nutrien

$55.95

0.94 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 06

    Nov

ABBV

AbbVie

$98.79

0.6 (0.61%)

, LYB

LyondellBasell

$113.07

1.155 (1.03%)

12:25
08/18/18
08/18
12:25
08/18/18
12:25
Periodicals
StAbbVie, Starbucks among dividend standouts, Barron's says »

AbbVie (ABBV),…

ABBV

AbbVie

$98.79

0.6 (0.61%)

LYB

LyondellBasell

$113.07

1.155 (1.03%)

AVGO

Broadcom

$209.27

0.6 (0.29%)

RF

Regions Financial

$19.48

0.09 (0.46%)

SBUX

Starbucks

$53.58

0.53 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

BV

BrightView

$17.49

-0.06 (-0.34%)

12:21
08/18/18
08/18
12:21
08/18/18
12:21
Periodicals
Sunny outlook for BrightView, Barron's says »

BrightView's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$42.26

1.15 (2.80%)

, CSIQ

Canadian Solar

$13.12

0.02 (0.15%)

11:18
08/18/18
08/18
11:18
08/18/18
11:18
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

HOG

Harley-Davidson

$42.26

1.15 (2.80%)

CSIQ

Canadian Solar

$13.12

0.02 (0.15%)

FSLR

First Solar

$50.98

0.18 (0.35%)

JASO

JA Solar

$0.00

(0.00%)

SUNEQ

SunEdison

$0.00

(0.00%)

SPWR

SunPower

$6.65

0.06 (0.91%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

PEP

PepsiCo

$114.98

0.7 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

LYV

Live Nation

$48.15

-0.53 (-1.09%)

17:46
08/17/18
08/17
17:46
08/17/18
17:46
Hot Stocks
Live Nation CFO discloses sale of 40K shares of common stock »

Live Nation CFO Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

, XLU

Utilities SPDR

$54.50

0.25 (0.46%)

17:40
08/17/18
08/17
17:40
08/17/18
17:40
General news
Week ending ETF Scorecard: Consumer Staples outperforms, Energy skids »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

XLU

Utilities SPDR

$54.50

0.25 (0.46%)

IYR

DJ US Real Estate Index Fund

$83.16

0.765 (0.93%)

XLP

Consumer Staples Sector SPDR

$55.02

0.39 (0.71%)

XLY

Consumer Discretionary Sector SPDR

$112.51

0.11 (0.10%)

XLB

S&P Select Materials SPDR

$58.41

0.41 (0.71%)

XLF

Financial Select Sector

$28.16

0.055 (0.20%)

XLV

Health Care Select Sector SPDR

$91.12

0.33 (0.36%)

XLK

Technology Select Sector SPDR

$73.17

0.14 (0.19%)

XLI

Industrial Select Sector SPDR

$76.26

0.47 (0.62%)

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

SLV

iShares Silver Trust

$13.93

0.16 (1.16%)

USO

United States Oil Fund

$13.70

0.065 (0.48%)

UNG

United States Natural Gas Fund

$24.18

0.295 (1.24%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.03

0.08 (0.09%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.97

0.11 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.99

0.16 (0.13%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.49

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$83.28

0.03 (0.04%)

IWD

iShares Russell 1000 Value

$126.16

0.6 (0.48%)

IWF

iShares Russell 1000 Growth

$150.80

0.27 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

17:33
08/17/18
08/17
17:33
08/17/18
17:33
Hot Stocks
SPDR Gold Trust holdings fall to 772.24MT from 773.41MT »

This is the 5th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$85.04

0.37 (0.44%)

17:30
08/17/18
08/17
17:30
08/17/18
17:30
Hot Stocks
Green Dot exec Dent sells 7,754 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMSI

Smith Micro

$2.49

-0.01 (-0.40%)

17:17
08/17/18
08/17
17:17
08/17/18
17:17
Syndicate
Breaking Syndicate news story on Smith Micro »

Smith Micro files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDRA

ENDRA Life Sciences

$2.70

0.2 (8.00%)

17:14
08/17/18
08/17
17:14
08/17/18
17:14
Syndicate
Breaking Syndicate news story on ENDRA Life Sciences »

ENDRA Life Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.